Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Description

The aim of this study was to determine if the use of a standard treatment (ivabradine) to lower heart rate can reduce cardiovascular death and morbidity. Among this double-blind, placebo-controlled, parallel-group trial, 5,479 subjects received 5 mg of ivabradine and 5,438 received placebo. Results showed that ivabradine treatment was associated with a placebo-corrected reduction in heart rate of 6 bpm at 12 months and 5 bpm at 24 months. Ivabradine did not affect the primary composite endpoint of cardiovascular death, admission to hospital for acute myocardial infarction, or admission to hospital for new-onset or worsening heart failure. However, ivabradine did reduce the incidence of endpoints related to coronary artery disease, namely admission to hospital for fatal and non-fatal acute myocardial infarction.